Adjunctive antiplatelet therapy in acute myocardial infarction: The road to improved infarct-related artery patency

Journal of Thrombosis and Thrombolysis

Volumn 4, Issue 3-4, 1997, Pages 353-355

  Alexander, John H ^a   Harrington, Robert A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glycoprotein IIb IIIa inhibitors; Myocardial infarction

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; INTERGRILIN; LAMIFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CORONARY ARTERY; FIBRINOLYTIC THERAPY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL;

EID: 0030879876     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008845315933     Document Type: Short Survey

References (13)

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
2. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-622.
3. Simes RJ, Topol EJ, Holmes DR, et al., for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-1928.
4. Lincoff AM, Topol EJ. Illusion of reperfusion: Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;88:1361-1372.
5. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:342-250, 310-318.
6. Coller BS. Antiplatelet agents in the prevention and therapy of thrombosis. Ann Rev Med 1992;43:171-180.
7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of Intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-359.
8. Kleiman NS, Ohman M, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI 8) pilot study. J Am Coll Cardiol 1993;22:381-389.
9. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1993;330:956-961.
10. Lincoff AM, Califf RM, Anderson K, Weisman HF, Topol EJ, for the EPIC Investigators. Striking clinical benefit with platelet GP IIb/IIIa inhibition by c7E3 among patients with unstable angina: Outcome in the EPIC trial (abstr). Circulation 1994;90(Suppl I):1-21.
11. Ohman EM, Kleiman NS, Gacioch G, et al., for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-854.
12. The GUSTO-IIb trial results. Presented at the the Annual Scientific Session of the American College of Cardiology, Orlando, Florida, March 24-27, 1996.
13. Moliterno DJ, Harrington RA, Califf RM, Rapold HJ, Topol EJ, for the PARADIGM Investigators. Randomized, placebo-controlled study of lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) study. J Thromb Thrombol 1995;2:165-169.